Close Menu

NEW YORK – OpGen said after the close of the market on Friday that it received a notice from Nasdaq that as of June 30 the company does not comply with a listing requirement calling for a minimum shareholder equity of $2.5 million.

As a result, the Gaithersburg, Maryland-based developer of antibiotic-resistance testing technology could face delisting action by Nasdaq. OpGen has 45 calendar days to submit a plan to regain compliance. If Nasdaq accepts the plan, it can grant the company an extension of up to 180 calendar days to become compliant with the listing requirement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new paper says an effort to introduce gene drives into mosquitos altered the genetic makeup of the local mosquitos, but the company behind the project says the paper is flawed.

Virginia's Department of Forensic Science is offering attorneys a course on DNA testing, the Virginian-Pilot reports.

Researchers examine changes in the genomes of emmer wheat populations where the climate has warmed, the BBC reports.

In Cell this week: microinjection of CRISPR-Cas9 enables targeted mutations in Anolis, melanoma proteomic profiling, and more.